PerkinElmer Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $113.17
- Today's High:
- $116.735
- Open Price:
- $115.65
- 52W Low:
- $113.17
- 52W High:
- $150.0132
- Prev. Close:
- $115.24
- Volume:
- 553006
Company Statistics
- Market Cap.:
- $14.46 billion
- Book Value:
- 58.455
- Revenue TTM:
- $3.31 billion
- Operating Margin TTM:
- 25.96%
- Gross Profit TTM:
- $2.04 billion
- Profit Margin:
- 17.19%
- Return on Assets TTM:
- 3.69%
- Return on Equity TTM:
- 7.06%
Company Profile
PerkinElmer Inc had its IPO on 1983-04-06 under the ticker symbol PKI.
The company operates in the Healthcare sector and Diagnostics & Research industry. PerkinElmer Inc has a staff strength of 16,700 employees.
Stock update
Shares of PerkinElmer Inc opened at $115.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $113.17 - $116.74, and closed at $114.21.
This is a -0.89% slip from the previous day's closing price.
A total volume of 553,006 shares were traded at the close of the day’s session.
In the last one week, shares of PerkinElmer Inc have slipped by -10.77%.
PerkinElmer Inc's Key Ratios
PerkinElmer Inc has a market cap of $14.46 billion, indicating a price to book ratio of 2.5693 and a price to sales ratio of 3.6825.
In the last 12-months PerkinElmer Inc’s revenue was $3.31 billion with a gross profit of $2.04 billion and an EBITDA of $1.29 billion. The EBITDA ratio measures PerkinElmer Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PerkinElmer Inc’s operating margin was 25.96% while its return on assets stood at 3.69% with a return of equity of 7.06%.
In Q1, PerkinElmer Inc’s quarterly earnings growth was a negative -32.4% while revenue growth was a negative 27.9%.
PerkinElmer Inc’s PE and PEG Ratio
- Forward PE
- 22.5225
- Trailing PE
- 41.4532
- PEG
- 4.0183
Its diluted EPS in the last 12-months stands at $2.78 per share while it has a forward price to earnings multiple of 22.5225 and a PEG multiple of 4.0183. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PerkinElmer Inc’s profitability.
PerkinElmer Inc stock is trading at a EV to sales ratio of 4.6088 and a EV to EBITDA ratio of 15.0456. Its price to sales ratio in the trailing 12-months stood at 3.6825.
PerkinElmer Inc stock pays annual dividends of $0.28 per share, indicating a yield of 0.24% and a payout ratio of 4.28%.
Balance sheet and cash flow metrics
- Total Assets
- $14.64 billion
- Total Liabilities
- $1.56 billion
- Operating Cash Flow
- $1.86 billion
- Capital Expenditure
- $20.95 million
- Dividend Payout Ratio
- 4.28%
PerkinElmer Inc ended 2024 with $14.64 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $14.64 billion while shareholder equity stood at $8.03 billion.
PerkinElmer Inc ended 2024 with $0 in deferred long-term liabilities, $1.56 billion in other current liabilities, 125981000.00 in common stock, $5.51 billion in retained earnings and $6.51 billion in goodwill. Its cash balance stood at $2.27 billion and cash and short-term investments were $2.46 billion. The company’s total short-term debt was $479,423,000 while long-term debt stood at $3.88 billion.
PerkinElmer Inc’s total current assets stands at $3.80 billion while long-term investments were $0 and short-term investments were $193.96 million. Its net receivables were $586.92 million compared to accounts payable of $266.88 million and inventory worth $429.42 million.
In 2024, PerkinElmer Inc's operating cash flow was $1.86 billion while its capital expenditure stood at $20.95 million.
Comparatively, PerkinElmer Inc paid $0.04 in dividends in 2024.
Other key metrics
- Current Trading Price
- $114.21
- 52-Week High
- $150.0132
- 52-Week Low
- $113.17
- Analyst Target Price
- $151.93
PerkinElmer Inc stock is currently trading at $114.21 per share. It touched a 52-week high of $150.0132 and a 52-week low of $150.0132. Analysts tracking the stock have a 12-month average target price of $151.93.
Its 50-day moving average was $128.04 and 200-day moving average was $133.94 The short ratio stood at 5.07 indicating a short percent outstanding of 0%.
Around 26.9% of the company’s stock are held by insiders while 8625.5% are held by institutions.
Frequently Asked Questions About PerkinElmer Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.